ENOV — Enovis Corporation stock price, charts and financials

QT78Enovis Corporation

Enovis Corporation (NYSE: ENOV) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
30.86
-0.56-1.78%
ENOVQT78Enovis Corporation·NYSE
30.86-1.78%
TA
Loading chart...
Screen all →
Snapshot
Index-P/E-EPS (ttm)-20.02Insider Own9.07%Shs Outstand57.56MPerf Week4.54%
Market Cap1.78BForward P/E7.56EPS next Y4.08Insider Trans0.20%Shs Float56.59MPerf Month19.15%
Enterprise Value3.15BPEG-EPS next Q-Inst Own-Short Float14.74%Perf Quarter32.22%
Income-1.14BP/S0.78EPS this Y118.20%Inst Trans-Short Ratio7.16Perf Half Y39.20%
Sales2.28BP/B1.20EPS next Y11.99%ROA-29.68%Short Interest8.34MPerf YTD15.84%
Book/sh25.69P/C53.83EPS next 5Y10.82%ROE-60.13%52W High34.28 -9.98%Perf Year19.89%
Cash/sh0.57P/FCF46.71EPS past 3/5Y-ROIC1.87%52W Low19.14 61.23%Perf 3Y-51.22%
Dividend Est.-EV/EBITDA-Sales past 3/5Y12.88% 14.93%Gross Margin56.81%Volatility4.17% 4.96%Perf 5Y-60.09%
Dividend TTM-EV/Sales1.38EPS Y/Y TTM-34.09%Oper. Margin2.70%ATR (14)1.48Perf 10Y-36.93%
Dividend Ex-Date-Quick Ratio1.05Sales Y/Y TTM8.11%Profit Margin-49.91%RSI (14)65.34Recom2.23
Dividend Gr. 3/5Y-Current Ratio2.04EPS Q/Q9.88%SMA2012.51%Beta1.13Target Price41.00
Payout0.00%Debt/Eq0.92Sales Q/Q5.37%SMA5026.39%Rel Volume1.16Prev Close31.42
Employees7,802LT Debt/Eq0.88EarningsAug 06SMA20021.07%Avg Volume1.18MPrice30.86
IPO DateMay 08, 2008Option/ShortYes / YesEPS/Sales Surpr.9.54% 2.99%Net Debt/EBITDA-1.84Volume1,365,659Change-1.78%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-28-26ReiteratedUBSBuy$50$51
Jul-08-26InitiatedBMO CapitalOutperform$29
Jul-06-26ReiteratedEvercore ISI GroupOutperform$36$32
May-08-26ReiteratedEvercore ISI GroupOutperform$40$36
Feb-26-26ReiteratedNeedhamBuy$65$52
Jan-06-26InitiatedBTIGBuy$41
Jan-05-26ReiteratedEvercore ISIOutperform$44$40
Jan-05-26ReiteratedUBSBuy$50
Dec-17-25ReiteratedCanaccord GenuityBuy$50
Jul-02-24ReiteratedEvercore ISI GroupOutperform$62
Latest News
Jul-21-26
Jul-17-26
Jul-13-26
Jul-10-26
Jul-06-26
Jul-03-26
Company

Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2,2792,2482,1081,7071,5631,4261,1213,3273,667
Cost of Goods Sold Incl. D&A9849039277166946495171,9262,534
Gross Profit1,2951,3451,1819918697786041,4011,133
Selling, General and Administrative Excl. Other1,0571,0709398307736665151,132818
Research and Development1241209175614934034
Other Operating Expense5217492615110712512165-34
Operating Income61-19-776-66-71-63-66204237
Interest Expense5735572025295312049
Unusual Expense
Non-Operating Income (Expense)-1,105-1,106101894-300-34-5
Net Income Before Taxes-1,102-1,159-823-67-2-122-11950183
Income Taxes33224-1336-20-45320
Consolidated Net Income-1,138-1,184-825-33-137243-528140
Net Income From Continuing Operations-1,134-1,182-827-54-38-102-7419122
Net Income-1,138-1,184-825-33-137243-528140
EPS (Recurring)-20.02-20.86-14.93-0.61-0.28-2.021.130.423.50
EPS (Basic, Before Extraordinaries)-20.02-20.86-14.93-0.61-0.28-2.021.130.423.50
EPS (Diluted)-20.02-20.86-14.93-0.61-0.28-2.021.110.413.48
EBITDA-749-830-481170242170180406330
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio59.30152.7210.34
Price To Sales Ratio0.770.681.141.801.852.832.700.850.39
Gross Margin56.8259.8356.0258.0655.6054.5653.8842.1130.90
Operating Margin2.68-0.85-36.81-3.87-4.54-4.42-5.896.136.46
Net Margin-49.93-52.67-39.14-1.93-0.835.053.84-15.873.82
Shares Outstanding575755555451464540
Market Capitalization1,7591,5182,4133,0812,8904,0353,0282,8181,439
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$38.32$33.16$27.99$22.82$17.66 Close Price0.00K115.95K231.89K347.84K463.79KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Engert OliverChief Administrative OfficerJun 15 '26Buy20.921,00020,92053,640Jun 16
Engert OliverChief Administrative OfficerJun 11 '26Buy21.621,20025,94851,840Jun 15
Engert OliverChief Administrative OfficerJun 10 '26Buy23.001,00023,00050,640Jun 11
Engert OliverChief Administrative OfficerJun 01 '26Buy22.221,00022,22049,640Jun 03
Engert OliverChief Administrative OfficerMar 13 '26Buy23.741,00023,74048,640Mar 16
Engert OliverChief Administrative OfficerMar 10 '26Buy23.931,00023,93047,640Mar 12
Engert OliverChief Administrative OfficerMar 09 '26Buy23.391,00023,39046,640Mar 10
Engert OliverChief Administrative OfficerMar 06 '26Buy24.4175018,31045,640Mar 10
Engert OliverChief Administrative OfficerMar 04 '26Buy25.102506,27544,890Mar 05
Engert OliverChief Administrative OfficerMar 03 '26Buy24.771,00024,77044,640Mar 05
Engert OliverChief Administrative OfficerFeb 27 '26Buy25.501,00025,50043,640Mar 03
PRYOR DANIEL Aother: Former EVP, Strategy & Bus DevDec 09 '25Sale27.211,66545,2980Dec 11
KLECKNER JOHNPrincipal Accounting OfficerNov 25 '25Buy30.322,46874,83012,302Nov 28
McDonald DamienChief Executive OfficerSep 11 '25Buy30.976,457199,973102,753Sep 11
Tandy Bradley JSVP and Chief Legal OfficerAug 22 '25Buy31.413,200100,51243,515Aug 25
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.